BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw an upside of 3.58% to close Friday at $14.46 after adding $0.5 on the day. The 5-day average trading volume is 2,309,140 shares of the company’s common stock. It has gained $14.48 in the past week. An average of 2,491,855 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,778,862.
BCRX’s 1-month performance is -5.18% or -$0.50 on its low of $13.10 reached on 10/04/21. The company’s shares have touched a 52-week low of $3.46 and high of $18.48, with the stock’s rally to the 52-week high happening on 08/06/21. YTD, BCRX has achieved 94.09% or $7.01. However, the current price is down -21.75%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 15, 26 days have gone by since the last insider trading activity for BioCryst Pharmaceuticals Inc. (BCRX). ABERCROMBIE GEORGE B (Director) most recently sold 5,000 shares at $15.06 per share on Sep 15. This transaction cost the insider $75,300. Director, LEE KENNETH B JR, sold 6,000 shares at a price of $15.35 on Sep 13. Then, on Sep 10, Director ABERCROMBIE GEORGE B sold 74,000 shares at a price of $15.09 per share. This transaction amounted to $1,116,660.
BioCryst Pharmaceuticals Inc. (BCRX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 31.93 for the sector.BCRX stock has a beta of 2.56. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 31.57.
BioCryst Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 2.20, with the current ratio over the same period at 2.30 meaning that BCRX stock is able to fulfill its debt obligations. In terms of profitability, the gross margin trailing 12 months is 90.10%. The trailing 12-month EBITDA margin is -948.70%. The firm’s gross profit as reported stood at $16.26 million against revenue of $17.81 million.
For the quarterly period ending June 29 this year, BioCryst Pharmaceuticals Inc.’s cash and short-term investments amounted to $8.11 million against total debt of $298.74 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected BCRX to announce -$0.24 per share in earnings in its latest quarter, but it posted -$0.24, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$29.7 million. BCRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 383.36 million, with total debt at $298.74 million. Shareholders hold equity totaling $178.87 million
Let’s look briefly at BioCryst Pharmaceuticals Inc. (BCRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 50.11% to suggest the stock is trending Neutral, with historical volatility in this time period at 48.34%.
The stock’s 5-day moving average is $13.80, reflecting a +5.32% or $0.73 change from its current price. BCRX is currently trading -4.87% above its 20-day SMA, +0.56% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -13.72% and +90.51% respectively.
Stochastic %K and %D was 34.10% and 24.86% and the average true range (ATR) pointed at 0.58. The RSI (14) points at 47.14%, while the 14-day stochastic is at 52.71% with the period’s ATR at 0.60. The stock’s 9-day MACD Oscillator is pointing at -0.04 and -0.49 on the 14-day charts.
In the most recent analyst report for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Jefferies downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for BCRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate BCRX as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 8 have offered a “buy” rating.
What is BCRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $16.00 and a high of $30.00, with their median price target at $21.00. Looking at these predictions, the average price target given by analysts is for BioCryst Pharmaceuticals Inc. (BCRX) stock is $21.27.